Endothelial-derived vasoactive mediators in polycystic kidney disease

Slides:

Advertisements

Similar presentations

Renal neuronal nitric oxide synthase protein expression as a marker of renal injury Attila J. Szabo, Laszlo Wagner, Aaron Erdely, Kim Lau, Chris Baylis.

Advertisements

Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure William C. Wolf, Hideaki.

Volume 66, Issue 1, Pages (July 2004)

Volume 64, Issue 6, Pages (December 2003)

Volume 66, Issue 4, Pages (October 2004)

Cyril H. Barton, Zehnmin Ni, Nosratola D. Vaziri Kidney International

Membranous nephropathy: When and how to treat

Volume 61, Issue 3, Pages (March 2002)

Volume 61, Issue 2, (February 2002)

Volume 68, Issue 5, Pages (November 2005)

Ralph Witzgall, Bettina Kränzlin, Norbert Gretz, Nicholas Obermüller

Overexpression of transforming growth factor–β1 correlates with increased synthesis of nitric oxide synthase in varicose veins Theresa Jacob, PhD, Anil.

Volume 59, Issue 5, Pages (May 2001)

Volume 87, Issue 2, Pages (February 2015)

Overcoming barriers that inhibit proper treatment of anemia

Volume 64, Issue 2, Pages (August 2003)

Nosratola D. Vaziri, Kaihui Liang, Yaoxian Ding Kidney International

Kidney immune cell infiltration and oxidative stress contribute to prenatally programmed hypertension Tyrus Stewart, Flavia F. Jung, Jennifer Manning,

Volume 68, Issue 4, Pages (October 2005)

Volume 68, Issue 5, Pages (November 2005)

Volume 59, Issue 3, Pages (March 2001)

Volume 61, Issue 1, Pages (January 2002)

Volume 87, Issue 2, Pages (February 2015)

Volume 70, Issue 11, Pages (December 2006)

Dominique A. Joly, Jean-Pierre Grünfeld Kidney International

Volume 71, Issue 11, Pages (June 2007)

Volume 62, Issue 3, Pages (September 2002)

Tight blood pressure control decreases apoptosis during renal damage

Thomas Quaschning, Jan Galle, Christoph Wanner

Volume 75, Issue 2, Pages (January 2009)

Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure William C. Wolf, Hideaki.

Volume 79, Issue 4, Pages (February 2011)

Volume 57, Issue 2, Pages (October 2000)

Volume 68, Issue 6, Pages (December 2005)

Volume 58, Issue 2, Pages (August 2000)

Volume 64, Issue 1, Pages (July 2003)

Volume 66, Issue 1, Pages (July 2004)

Volume 61, Issue 5, Pages (May 2002)

Volume 71, Issue 9, Pages (May 2007)

Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis H.-C. Yang, L.-J. Ma, J. Ma, A.B. Fogo

Distribution of postsynaptic density proteins in rat kidney: Relationship to neuronal nitric oxide synthase Akihiro Tojo, David S. Bredt, Christopher.

Volume 62, Issue 3, Pages (September 2002)

Role of endothelin and nitric oxide imbalance in the pathogenesis of hypoxia-induced arterial hypertension Zhenmin Ni, Shahrooz Bemanian, Salah D. Kivlighn,

Effects of NADPH oxidase inhibitor in diabetic nephropathy

Volume 54, Issue 5, Pages (November 1998)

Volume 70, Issue 1, Pages (July 2006)

Volume 81, Issue 8, Pages (April 2012)

Circulating endothelial nitric oxide synthase inhibitory factor in some patients with chronic renal disease Shen Xiao, Laszlo Wagner, Rebecca J. Schmidt,

Volume 60, Issue 1, Pages (July 2001)

Volume 62, Issue 1, Pages (July 2002)

Volume 63, Issue 1, Pages (January 2003)

Volume 69, Issue 7, Pages (April 2006)

Lamivudine in hepatitis B-associated membranous nephropathy

Yasunori Kitamoto, Katsuhiko Matsuo, Kimio Tomita Kidney International

Volume 58, Issue 3, Pages (September 2000)

Volume 60, Issue 5, Pages (November 2001)

Volume 75, Issue 3, Pages (February 2009)

The course of the remnant kidney model in mice

Aldosterone in the development and progression of renal injury

Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension Julian Segura, Carlos Campo, Luis M. Ruilope Kidney.

Salt sensitivity in genetically hypertensive rats of the Lyon strain

Is it the low-protein diet or simply the salt restriction?

Volume 71, Issue 9, Pages (May 2007)

Inhibition of the renin–angiotensin system: is more better?

Volume 62, Issue 5, (November 2002)

Volume 72, Issue 11, Pages (December 2007)

Volume 61, Issue 1, Pages (January 2002)

J. Ma, A. Weisberg, J.P. Griffin, D.E. Vaughan, A.B. Fogo, N.J. Brown

Volume 61, Issue 3, Pages (March 2002)

Volume 56, Issue 6, Pages (December 1999)

Presentation transcript:

Endothelial-derived vasoactive mediators in polycystic kidney disease Muna A. Al-Nimri, Radko Komers, Terry T. Oyama, Arohan R. Subramanya, Jessie N. Lindsley, Sharon Anderson Kidney International Volume 63, Issue 5, Pages 1776-1784 (May 2003) DOI: 10.1046/j.1523-1755.2003.00913.x Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 1 Systolic blood pressure (SBP) before (6 weeks) and after (12 weeks) L-NAME. *P < 0.05 vs. control; †P < 0.05 vs. C/L-NAME; ‡P < 0.05 vs. cystic; #P < 0.05 vs. 6 weeks in same group. Kidney International 2003 63, 1776-1784DOI: (10.1046/j.1523-1755.2003.00913.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 2 Urinary protein excretion (UprotV) before (6 weeks) and after (12 weeks) L-NAME. *P < 0.05 vs. control; †P < 0.05 vs. C/L-NAME; ‡P < 0.05 vs. cystic; #P < 0.05 vs. 6 weeks in same group. Kidney International 2003 63, 1776-1784DOI: (10.1046/j.1523-1755.2003.00913.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 3 Urinary nitrite + nitrate excretion (UNOxV) before (6 weeks) and after (12 weeks) L-NAME. *P < 0.05 vs. control; †P < 0.05 vs. C/L-NAME; ‡P < 0.05 vs. cystic; #P < 0.05 vs. 6 weeks in same group. Kidney International 2003 63, 1776-1784DOI: (10.1046/j.1523-1755.2003.00913.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 4 Renal endothelin-1 (ET-1) in control and cystic rats. *P < 0.05 vs. control; †P < 0.05 vs. C/NAME; ‡P < 0.05 vs. cystic. Kidney International 2003 63, 1776-1784DOI: (10.1046/j.1523-1755.2003.00913.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 5 Representative Western blots of endothelial nitric oxide synthase (eNOS) in control and cystic rats, and cystic rats treated with L-NAME. (A) Membrane-bound eNOS. (B) Cytosolic eNOS. *P < 0.01 vs. control; †P < 0.05 vs. cystic/L-NAME; ‡P < 0.05 vs. cystic. Kidney International 2003 63, 1776-1784DOI: (10.1046/j.1523-1755.2003.00913.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 6 Immunolocalization of eNOS protein (arrows). Immunoreactive eNOS was fully expressed in renal arterioles and glomeruli of noncystic control rats (A, C), but undetectable in vascular structures of cystic rats (B, D). Kidney International 2003 63, 1776-1784DOI: (10.1046/j.1523-1755.2003.00913.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 7 Immunohistochemistry depicting distribution of nNOS (arrows). Control rats demonstrated typical distribution of nNOS in MD cells (A). In contrast, nNOS immunoreactivity was scarce in MD cells of cystic rats (B). Cystic rats demonstrated occasional ectopic clusters of nNOS-positive tubular cells (C). Non-immune serum controls showed no staining (D). Kidney International 2003 63, 1776-1784DOI: (10.1046/j.1523-1755.2003.00913.x) Copyright © 2003 International Society of Nephrology Terms and Conditions